NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CervoMed Inc. (CRVO) Stock Analysis

CervoMed Inc. (CRVO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRVO

$2.56

+$0.02 (+0.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRVO with… →

CRVO Key Statistics

As of Sep 4, 2026
Trading
Open
$2.54
Previous Close
$2.54
Day's Range
2.52–2.58
52-Week Range
2.13–10.74
Volume
108.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−4.31
Valuation
Market Cap
$38.70M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
116.83
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.12M
1-Year Return
−74.93%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
5.64M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRVO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−67.59%
2025+237.61%
2024−69.33%
2023+0.53%
2022−67.35%
2021−61.25%
2020+73.91%
2019−76.88%
2018−88.76%
2017−47.79%
2016 (partial year)−71.75%

As of September 4, 2026.

CRVO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.97M—
2024$0.00−$16.29M—
2023$0.00−$2.17M—
2022$0.00−$5.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$28.29M−$26.97M—
2024$0.00—−$18.23M−$16.29M—
2023$0.00—−$7.81M−$2.17M—
2022$0.00—−$3.48M−$5.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRVO Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRVOBiotechnology medianvs median
P/S ratio116.8315.267.7x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CervoMed Inc. (CRVO) carries a market capitalisation of $38.70M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 15.

Over the past 52 weeks the price has ranged from $2.13 to $10.74. The most recent close on file for CRVO is $2.56, dated September 4, 2026. That is +$0.02 (+0.79%) against the previous close. The latest close sits 20.19% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $26.97M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.21.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 116.83 times revenue. On price-to-sales that is 7.7 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −74.93%. Across 10 years the annualized return works out at −56.20%. The reported beta is −4.31. Daily returns over the trailing 10 years annualize to a volatility of 283.42%.

Growth & Income

The record shows no dividend for CRVO.

The strongest complete calendar year on file is 2025 at +237.61%; the weakest is 2018 at −88.76%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −67.59%.

Peer Comparison

CervoMed Inc. (CRVO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CervoMed Inc. CRVO $38.70M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CervoMed Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Visit website →